Table 6.
Antibody indices, CSF antibody concentrations and CSF PCR results for SARS-CoV-2, numerous other viruses, including herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein Barr virus (EBV), human herpes virus 6 (HHV6), measles virus (M), and rubella virus (R), and Borrelia burgdorferi (BB) in group I
| Units | Total cohort | |
|---|---|---|
| Positive antibody indices | ||
| AI SARS-CoV-2, IgG | Samples | 2/20 (10%) |
| Patients | 2/19 (10.5%) | |
| AI SARS-CoV-2, IgM | Samples | 1/4 (25%) |
| Patients | 1/4 (25%) | |
| AI SARS-CoV-2, IgA | Samples | 1/4 (25%) |
| Patients | 1/4 (25%) | |
| AI HSV, IgG | Samples | 1/22 (4.5%) |
| AI EBV, IgG | Samples | 0/4 (0%) |
| AI CMV, IgG | Samples | 0/11 (0%) |
| AI B. burgdorferi, IgG | Samples | 0/21 (0%) |
| AI B. burgdorferi, IgM | Samples | 1/18 (5.6%) |
| AI measles virus (M), IgG | Samples | 0/1 (0%) |
| AI rubella virus (R), IgG | Samples | 0/1 (0%) |
| AI varicella zoster virus (Z), IgG | Samples | 1/20 (5%) |
| MRZ reaction (M + R, M + Z, R + Z, or M + R + Z) | Samples | 0/1 (0%) |
| Patients | 0/1 (0%) | |
| Elevated CSF antibody levels | ||
| SARS-CoV-2, IgG | Samples | 20/29 (69%) |
| Patients | 20/28 (71.4%) | |
| SARS-CoV-2, IgM | Samples | 1/4 (25%) |
| Patients | 1/4 (25%) | |
| SARS-CoV-2, IgA | Samples | 1/4 (25%) |
| Patients | 1/4 (25%) | |
| Positive CSF PCR | ||
| SARS-CoV-2 | Samples | 0/76 (0%) |
| Patients | 0/75 (0%) | |
| HSV | Samples | 0/59 (0%) |
| VZV | Samples | 1/21 (4.8%) |
| CMV | Samples | 0/20 (0%) |
| EBV | Samples | 0/6 (0%) |
| HHV6 | Samples | 0/5 (0%) |
| Neurotropic viruses (panel) | Samples | 1/2 (50%) |